Ulka Vaishampayan M.D__肾癌_美国专家_我的专家_全球会诊

您现在的位置是：首页>权威专家> 肾癌

Ulka Vaishampayan M.D

所在科室：外科

就职医院：Karmanos cancer center

医生擅长：

在线咨询医学顾问电话热线：400-666-7998

医生介绍

· Gender

· Female

· Multidisciplinary Team(s)

· Genitourinary Oncology
Phase 1

· Department/Research Program(s)

· Department of Oncology

· Cancer Type(s)

· Adrenal Cancer
Bladder cancer
Kidney Cancer
Prostate Cancer
Testicular Cancer

· Contact Info

· Email:
vaishamu@karmanos.org

Education

· Fellowship
Hematology/oncology Fellowship, Wayne State University, Detroit, MI
Fellowship
Chief Fellow, Hematology/Oncology, Wayne State University, Detroit, MI
Medical School
Byramjee Jeejeebhoy Medical School
Residency
Residency in Medicine, Wayne State University, Detroit, Michigan

· Professional Memberships/Associations

· American Society of Clinical Oncology
Southwest oncology Group

· Board Certifications

· American Board of Medical Oncology

· Clinical Interests

· Medical Oncology

· Research Interests

· Reaserch related to clinical trials in prostate, kidney and bladder cancers, overcoming resistance to current therapies and exploring novel treatments and combinations in prostate cancer, as well as development of prognostic and predictive markers in kidney cancer

· Profile

· Dr. Vaishampayan has been providing patient care on staff at Karmanos since 2000. Her experience extends to research, as well as being a member of the editorial board for multiple oncology journal. In addition, she is a lecturer and educator at Wayne State University School of Medicine.

· Awards

· Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

· Publications

· Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25 PMID:23550669. Authors: Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, et al.
Phase II trial of satraplatin and bevacizumab in metastatic docetaxel pretreated castrate resistant prostate cancer. Urol Oncol. 2013 Feb 20. S1078-1439. PMID:23433892. Authors: Vaishampayan U, Heilbrun L, Smith D, Baranowski K, Dickow B, Figg W.
External Validation and Comparison with Other Models of the International metastatic Renal-Cell Carcinoma Database Consortium Prognostic Model: A Population-based Study. Lancet oncol 2013 Feb;14(2):141-148. Doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 98. PMID:23312463. Authors: Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N. Kollmannsberger C, Rini BI, Choueiri TK.
The Association of Clinical Outcome to First-line VEGF-Targeted Therapy with Clinical Outcome to Second-line VEGF-Targeted Therapy in metastatic Renal Cell Carcinoma Patients. For the International mRCC Database Consortium. Target Oncol. 2013 Jan 9. PMID:23300029. Authors: Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha Sy, Donskov FN, North S, Coueiri TK, Heng DY;
Cabozantinib as a Novel Therapy for Renal Cell Carcinoma. Curr oncol Rep. 2013 Jan 5. [Epub ahead of print] PMID:232929795]. Author: Vaishampayan U.